Lumida
/ORGO
⌘K
Organogenesis Holdings Inc

Organogenesis Holdings Inc

ORGO
$1.49USD-2.61%-0.04 today

MARKET CAP

191.7M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $2

52W RANGE

$1
$7

AI Summary

Stalk
Sell NowMedium

ORGO remains in a sustained downtrend on both medium- and long-term horizons, trading below all key moving averages with no active bullish patterns. Medium-term bias is bearish given persistent lower highs and lows and resistance at the 21/50 EMA zone. Short-term execution readiness is confirmed by a failed rally into the EMAs and rejection at moving-average resistance. Sell Now is advised at these resistance levels into the ongoing downtrend.

  • Q2 revenue rose 18% QoQ to $42.8 M, indicating sales rebound.
  • Restructuring cuts 138 jobs to save ~$18 M annually.
  • Q2 revenue fell 58% YoY to $42.8 M; advanced wound care sales down 61%.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$467.4M$450.9M$433.1M$482.0M$564.2M
YoY %+38.2%-3.5%-3.9%+11.3%+17.0%
P / Sales2.6x0.8x1.3x0.9x1.2x
EV / Sales2.8x0.9x1.4x0.8x1.3x
Gross Profit, Adj.$353.2M$345.9M$433.1M$482.0M$564.2M
YoY %+40.7%-2.1%+25.2%+11.3%+17.0%
Margin %75.6%76.7%100.0%100.0%100.0%
EV / Gross Profit3.7x1.2x1.4x0.8x1.3x
EBITDA, Adj.$88.9M$33.0M$27.9M$38.5M$74.5M
YoY %+154.8%-62.8%-15.6%+38.2%+93.2%
Margin %19.0%7.3%6.4%8.0%13.2%
EV / EBITDA14.9x12.9x22.2x10.3x10.0x
EBIT$72.2M$22.3M$12.5M$-1.3M$44.7M
YoY %+170.5%-69.1%-43.8%-110.2%+3583.6%
Margin %15.5%4.9%2.9%-0.3%7.9%
EV / EBIT18.3x19.1x49.4x-310.5x16.7x
Net Income$94.2M$15.5M$4.9M$-937,000$20.0M
YoY %+446.6%-83.5%-68.2%-118.9%+2236.8%
Net Margin20.2%3.4%1.1%-0.2%3.5%
EPS (GAAP)$0.70$0.12$0.04-$0.01$0.15
YoY %+366.7%-82.9%-66.7%-125.0%+1600.0%